As of the latest Form 4 filed Jul 9, 2026.
What Oncology Institute Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 24 most recent filings for TOI.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | 2026-07-07 | TZOUMAKAS KIMBERLY JO Director | AAward | +17.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-09 | 2026-07-07 | STOLPER MARK Director | AAward | +25.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-23 | Chernett Jorey 10% owner | PPurchase | +18.0K | $5.02 | $90.4K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-08 | Podnos Yale Chief Medical Officer | SSale | −23.5K | $5.38 | $126K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Chernett Jorey 10% owner | PPurchase | +12.0K | $4.75 | $57.0K | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-19 | Chernett Jorey 10% owner | PPurchase | +30.0K | $4.09 | $123K | No | Form 4 ↗ |
| 2026-04-16 | 2026-04-16 | Kaushal Mohit Director | SSale | −38.4K | $3.50 | $135K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Kaushal Mohit, Director | SSale | −57.3K | $3.50 | $201K | Yes (planned) | Form 4 ↗ |
| 2026-04-13 | 2026-04-09 | Chernett Jorey 10% owner | PPurchase | +20.0K | $3.10 | $62.0K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-27 | Langsam Jeffrey Chief Clinical Officer | AAward | +70.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-27 | England Kristin Chief Administrative Officer | AAward | +55.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-27 | Podnos Yale Chief Medical Officer | JOther | −16.2K | $3.07 | $49.7K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-27 | Podnos Yale, Chief Medical Officer | AAward | +66.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-27 | Carter Robert Ross Chief Financial Officer | JOther | −20.3K | $3.07 | $62.4K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-27 | Carter Robert Ross, Chief Financial Officer | AAward | −203K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-27 | Virnich Daniel Chief Executive Officer | JOther | −98.5K | $3.07 | $302K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-27 | Virnich Daniel, Chief Executive Officer | AAward | −671K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-27 | Chernett Jorey 10% owner | PPurchase | +27.4K | $2.96 | $81.2K | No | Form 4 ↗ |
| 2026-03-27 | 2026-03-26 | Chernett Jorey 10% owner | PPurchase | +50.0K | $3.15 | $158K | No | Form 4 ↗ |
| 2026-03-25 | 2026-03-24 | Chernett Jorey 10% owner | PPurchase | +125K | $3.11 | $389K | No | Form 4 ↗ |
| 2026-03-23 | 2026-03-20 | Chernett Jorey 10% owner | PPurchase | +25.0K | $3.35 | $83.8K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Virnich Daniel Chief Executive Officer | JOther | −11.8K | $3.59 | $42.5K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Carter Robert Ross Chief Financial Officer | JOther | −1.31K | $3.59 | $4.72K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Podnos Yale Chief Medical Officer | JOther | −3.42K | $3.59 | $12.3K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also TOI’s full analysis or the market-wide insider trading feed. The tabs above jump to TOI’s other SEC data.
Source: SEC Form 4 filings for TOI, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.